

AMENDMENTS TO THE CLAIMS:

Claim 1. (Previously Presented) Tamsulosin hydrochloride, ((R)-5-(2-(2-(2-ethoxyphenoxy) ethylamino)propyl)-2-methoxybenzenesulphonamide) hydrochloride, in the amorphous form, prepared by lyophilization of tamsulosin hydrochloride dissolved in a solution.

Claim 2. (Previously Presented) Tamsulosin hydrochloride in the amorphous form according to claim 1 characterised in that the amorphous tamsulosin hydrochloride has a DSC thermogram which exhibits an exothermic peak at about 100° C.

Claim 3. (Previously Presented) Tamsulosin hydrochloride in the amorphous form according to claim 1 characterised in that the amorphous tamsulosin hydrochloride has an IR spectrum which exhibits a band at about 3449 cm⁻¹.

Claim 4. (Previously Presented) Tamsulosin hydrochloride in the amorphous form according to claim 3 characterised in that the amorphous tamsulosin hydrochloride has an IR spectrum which exhibits the bands substantially as shown in Table 1.

Claim 5. (Previously Presented) Tamsulosin hydrochloride in the amorphous form according to claim 1 characterised in that the amorphous tamsulosin hydrochloride has an X-ray powder diffractogram which exhibits the absence of discrete diffractions which are characteristic of crystalline forms.

Claim 6. (Withdrawn) A process for the preparation of the amorphous form of tamsulosin hydrochloride characterised in that it comprises lyophilization of a solution of tamsulosin hydrochloride.

Claim 7. (Withdrawn) The process for the preparation of amorphous tamsulosin hydrochloride according to claim 6 wherein said solution of tamsulosin hydrochloride is aqueous solution.

Claim 8. (Cancelled)

Claim 9. (Withdrawn) The process for the preparation of amorphous tamsulosin hydrochloride according to claim 8 wherein said solution of tamsulosin hydrochloride is aqueous solution.

Claim 10. (Withdrawn) A pharmaceutical formulation comprising tamsulosin hydrochloride and one or more pharmaceutically acceptable excipients characterised in that it comprises tamsulosin hydrochloride in the amorphous form.

Claims 11.-15. (Cancelled)

Claim 16. (Previously Presented) Tamsulosin hydrochloride in the amorphous form according to claim 1 characterised in that, prior to lyophilization, the tamsulosin hydrochloride is dissolved in a solvent to form a mixture having a concentration of from about 0.5 grams tamsulosin hydrochloride per liter of solvent to about 5.0 grams of tamsulosin hydrochloride per liter of solvent.

Claim 17. (Previously Presented) The amorphous tamsulosin hydrochloride of claim 16 wherein, prior to lyophilization, the tamsulosin hydrochloride is dissolved in a solvent at a concentration of from about 1 gram tamsulosin hydrochloride per liter of solvent to about 5.0 grams of tamsulosin hydrochloride per liter of solvent.

Claim 18. (Previously Presented) The amorphous tamsulosin hydrochloride of claim 16 wherein, prior to lyophilization, the tamsulosin hydrochloride mixture remains frozen from about 12 hours to about 56 hours.

Claim 19. (Previously Presented) The tamsulosin hydrochloride of Claim 1 wherein the solution containing dissolved tamsulosin hydrochloride is an aqueous solution thereof.

Claim 20. (New) The tamsulosin hydrochloride of Claim 1 wherein the amorphous tamsulosin hydrochloride is at least 75% pure.